A Phase II Clinical Trial To Study The Efficacy And Safety Of Pembrolizumab (MK-3475) In Subjects With High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Bacillus Calmette-Guerin (BCG) Therapy